Movement Alert｜Tempus AI Intraday Decline 5.48%, Major Shareholder Continued Selling Pressure Compounded by Sector-Wide Weakness

Market Focus06-03

On June 3, Tempus AI fell 5.48% in regular trading, trading at $46.86/share, with trading volume of $89.20 million.

On the news front, the company's over-10% shareholder Eric Lefkofsky has been conducting intensive share disposals in recent sessions, exerting notable downward pressure on market sentiment. Concurrently, the Life Sciences Tools & Services sector traded broadly lower, with Thermo Fisher Scientific down 2.36%, IQVIA down 2.93%, Waters down 1.34%, Danaher down 1.11%, and Agilent down 0.68%, amplifying selling pressure on Tempus AI.

The decline follows a sharp rally driven by the FDA approval of Tempus AI's xT CDx next-generation sequencing platform for tumor-only comprehensive genomic profiling of solid tumors, which made Tempus the first laboratory with FDA companion diagnostic approval for both tumor-only and tumor-normal genomic profiling. The company expects the approval to deliver an estimated $200 increase in average selling price starting in 2027. Having accumulated significant short-term gains post-approval, the current pullback is viewed as a continuation of profit-taking and technical correction.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120100130?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 22:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120100130","market":"us","top_or_hot":-1,"title":"Movement Alert｜Tempus AI Intraday Decline 5.48%, Major Shareholder Continued Selling Pressure Compounded by Sector-Wide Weakness","media":"Market Focus","content":"<p><p>On June 3, Tempus AI fell 5.48% in regular trading, trading at $46.86/share, with trading volume of $89.20 million.</p><p>On the news front, the company's over-10% shareholder Eric Lefkofsky has been conducting intensive share disposals in recent sessions, exerting notable downward pressure on market sentiment. Concurrently, the Life Sciences Tools & Services sector traded broadly lower, with Thermo Fisher Scientific down 2.36%, IQVIA down 2.93%, Waters down 1.34%, Danaher down 1.11%, and Agilent down 0.68%, amplifying selling pressure on Tempus AI.</p><p>The decline follows a sharp rally driven by the FDA approval of Tempus AI's xT CDx next-generation sequencing platform for tumor-only comprehensive genomic profiling of solid tumors, which made Tempus the first laboratory with FDA companion diagnostic approval for both tumor-only and tumor-normal genomic profiling. The company expects the approval to deliver an estimated $200 increase in average selling price starting in 2027. Having accumulated significant short-term gains post-approval, the current pullback is viewed as a continuation of profit-taking and technical correction.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Tempus AI Intraday Decline 5.48%, Major Shareholder Continued Selling Pressure Compounded by Sector-Wide Weakness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Tempus AI Intraday Decline 5.48%, Major Shareholder Continued Selling Pressure Compounded by Sector-Wide Weakness\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-03 22:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 3, Tempus AI fell 5.48% in regular trading, trading at $46.86/share, with trading volume of $89.20 million.</p><p>On the news front, the company's over-10% shareholder Eric Lefkofsky has been conducting intensive share disposals in recent sessions, exerting notable downward pressure on market sentiment. Concurrently, the Life Sciences Tools & Services sector traded broadly lower, with Thermo Fisher Scientific down 2.36%, IQVIA down 2.93%, Waters down 1.34%, Danaher down 1.11%, and Agilent down 0.68%, amplifying selling pressure on Tempus AI.</p><p>The decline follows a sharp rally driven by the FDA approval of Tempus AI's xT CDx next-generation sequencing platform for tumor-only comprehensive genomic profiling of solid tumors, which made Tempus the first laboratory with FDA companion diagnostic approval for both tumor-only and tumor-normal genomic profiling. The company expects the approval to deliver an estimated $200 increase in average selling price starting in 2027. Having accumulated significant short-term gains post-approval, the current pullback is viewed as a continuation of profit-taking and technical correction.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEM","symbol_name":"Tempus AI","start_time":0,"source_url":"","article_id":"1120100130","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120100130","pubTimestamp":1780495652,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 3, Tempus AI fell 5.48% in regular trading, trading at $46.86/share, with trading volume of $89.20 million.On the news front, the company's over-10% shareholder Eric Lefkofsky has been...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEM":"Tempus AI"},"translate_title":"动感快讯|腾邦AI盘中跌5.48%大股东持续抛压叠加全板块疲弱","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":1},"content_text":"On June 3, Tempus AI fell 5.48% in regular trading, trading at $46.86/share, with trading volume of $89.20 million.On the news front, the company's over-10% shareholder Eric Lefkofsky has been conducting intensive share disposals in recent sessions, exerting notable downward pressure on market sentiment. Concurrently, the Life Sciences Tools & Services sector traded broadly lower, with Thermo Fisher Scientific down 2.36%, IQVIA down 2.93%, Waters down 1.34%, Danaher down 1.11%, and Agilent down 0.68%, amplifying selling pressure on Tempus AI.The decline follows a sharp rally driven by the FDA approval of Tempus AI's xT CDx next-generation sequencing platform for tumor-only comprehensive genomic profiling of solid tumors, which made Tempus the first laboratory with FDA companion diagnostic approval for both tumor-only and tumor-normal genomic profiling. The company expects the approval to deliver an estimated $200 increase in average selling price starting in 2027. Having accumulated significant short-term gains post-approval, the current pullback is viewed as a continuation of profit-taking and technical correction.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120100130","isCrawlerRequest":true}